Thesis

190 Part II Chapter 8 The mean interval between baseline Na[18F]F PET-CT and first follow-up Na[18F]F PET- CT after start of treatment was 18 months (range 12-26 months, n=15 pairs) and the mean number of cycles of denosumab given was 6 at an interval of 3months between denosumab injections (range: 4-9) in the subgroup of patients that started denosumab. Patient characteristics during baseline and first follow-up Na[18F]F PET-CT are displayed in table 3. Table 3. Patient demographics Baseline Follow up p-value Parameter Number of patients (n) 15 15 Female (n) 9 9 Age at scan (years) mean (SD) 46.7 (14.7) 48.3 (14.7) Biochemistry ALP (IU/L, ULN 98); median (IQR) 119 (83-143) 84 (64-106) 0.020 P1NP (ng/mL, ULN 59); median (IQR) 82 (51-237) 55 (34-112) 0.023 Clinical parameters BPI Average; median (IQR), n=14 (one missing) 5.00 (0.75-7.50) 3.50 (0.00-7.00) 0.173 bisphosphonates use, n (%) 13 (93) 5 (36) 0.001 denosumab 60mg every 3 months, n (%) 0 (0) 8 (57) 0.002 Ca/D3, n (%) 10 (71) 9 (64) 1.000 Imaging parameters SBS median (IQR) 15.8 (2.2-17.0) not repeated Cut-off SUV (g/mL) median (IQR) 8.5 (7.2-9.1) 7.7 (7.3-8.5) 0.233 SUVpeak (g/mL) median (IQR) 29 (18-34) 21 (13-30) 0.028 FTV (cm3) median (IQR) 199 (77-923) 97 (51-635) 0.030 FAS (%) median (IQR) 2.65 (1.13-18.6) 1.45 (0.78-8.40) n.d. SD= Standard deviation, ULN= Upper Limit of Normal, IQR= Inter Quartile Range, ALP= Alkaline Phosphatase, P1NP= total procollagen type 1 N-terminal propeptide, BPI= structured Brief Pain Inventory, SBS= Skeletal Burden Score on planar bone scintigraphy, SUV= Standard Uptake Value on PET-CT, FTV= Fluoride Tumor Volume, FAS = Fraction Affected Skeleton (=FTV divided by skeletal volume on CT), n.d.= could not be determined. Quantitative analysis of Na[18F]F PET-CT: normal vs pathological bone at baseline and follow-up

RkJQdWJsaXNoZXIy MjY0ODMw